Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
The facility in Hanko, Finland will be operation in 2018
May 19, 2016
By: Tim Wright
Editor-in-Chief, Contract Pharma
Fermion has unveiled plans to invest €30 million in a API manufacturing facility expansion. Beginning in 2018, the Hanko plant located in the south of Finland, will start operating new API manufacturing facilities including 76 m3 reactor space, incremental to Fermion’s current total reactor volume of 320 m3. With best-in-class automated systems, controlled material flows, isolators and smart infrastructure the new facilities will process not only standard but also potent APIs. There will be a reactor space of 25 m3 for OEB5 compounds—containment level down to 0,1 µg/m3—and the rest of the new capacity is equipped for compounds requiring a containment level of 1 – 10 µg/m3. With the new, modern facilities Fermion says it will be prepared to meet tightening regulatory requirements and better positioned to support both current and new business. “The expansion lifts Fermion to a new level in the global arena of API and especially HAPI manufacturing, improving Fermion’s capability to meet increasing demand. Fermion will continue to ensure high quality and delivery reliability of its products,” said Arto Toivonen, president, Fermion. “The new unit alone will be able to produce 100 metric tons HPAPI per year increasing the total production capacity of Fermion to over 400 metric tons API/year. Fermion’s scale of HPAPI development and production will now be complete with capabilities from grams to tons.” Fermion’s investment of €30 million in Hanko is the largest in the history of the company since 1970 and also turns a new page in the history of the Finnish pharmaceutical industry. The Hanko plant is Fermion’s largest production facility with an annual API capacity of approximately 300 metric tons. The Hanko plant supports the full scale of commercial API manufacturing, both generic and custom APIs. The plant consists of three operational units, two dedicated for intermediate production and the third, fully automated unit inaugurated in 2001 produces APIs. The plant is equipped with dryers and mills for API micronization and has a Buss loop reactor for hydrogenations as well as an on-site incinerator of VOC gases and a biological wastewater treatment facility. Construction of the new facility will start in the summer of 2016 and the inauguration will be celebrated in Q2 2018.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !